Phase II study of E7389 [eribulin], a halichondrin B analog, in patients with advanced non-small cell lung cancer (NSCLC), who progressed during or after platinum-based doublet chemotherapy stratified for prior taxane therapy.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2012
At a glance
- Drugs Eribulin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2009 Actual patient number (106) added as reported by ClinicalTrials.gov.
- 19 Aug 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.